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History of synovial biopsy in the diagnosis of
arthritis
Early histopathological studies of rheumatoid arthritis (RA)
were based on tissue samples obtained at surgery or at
postmortem examination. In 1932 a technique for obtain-
ing non-surgical synovial tissue for diagnostic purposes,
using a dental nerve extractor that was introduced into the
joint through a large-calibre needle, was first proposed [1].
The introduction of this technique to clinical practice was
never described. About 20 years later, early experiences
with needle biopsy of the synovium were published [2,3].
It was suggested that the procedure was safe and practi-
cal for use in both hospital wards and outpatient clinics.
However, because of their wide bore and the need for an
incision, these prototype biopsy needles tended to cause
significant trauma to the penetrated tissues. In 1963,
Parker and Pearson described a simplified 14-gauge
needle that did not require a skin incision [4]. They pub-
lished their experience of 125 procedures, almost all from
the suprapatellar pouch of the knee joint, with a very high
yield of adequate tissue for analysis. No serious complica-
tions were encountered. For about 30 years, the
Parker–Pearson needle, or a modification of it [5,6],
remained the instrument of choice when acquiring synovial
tissue for diagnostic or research purposes.
Arthroscopic techniques, which enable the selection of
synovial tissue under direct vision, were also developed
primarily to assist in the diagnosis of arthritis [7]. Early
studies by rheumatologists suggested a lack of associa-
tion between the arthroscopic findings and clinical, labora-
tory and radiological features of arthritis [8,9]. More
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Abstract
Synovial tissue is readily accessible by closed needle or arthroscopic biopsy. These techniques
provide adequate tissue for most diagnostic requirements. Examination of synovial tissue can assist in
the diagnosis of some joint infections, and in several atypical or rare synovial disorders. Histological
confirmation is not normally required for diagnosis of the common forms of inflammatory arthritis,
including rheumatoid arthritis (RA). In patients with either established or early RA, immunohistological
measures of inflammation in synovial tissue are associated with clinical measures of disease activity,
may predict the clinical outcome, and change in response to treatment. Surrogate markers of disease
activity and outcome that have been identified in synovial tissue include components of the cellular
infiltrate, and several mediators of inflammation and matrix degradation. There is evidence that the very
early introduction of disease-modifying therapy inhibits progressive structural damage maximally.
Clinicians exploiting this ‘window of opportunity’ therefore require very early indicators of the diagnosis
and outcome in patients who present with an undifferentiated inflammatory arthritis. Some
immunohistological features have been described that distinguish patients who are likely to develop
progressive RA and who might benefit most from early aggressive therapeutic intervention. In this
regard, the inclusion of pharmacogenomic and proteomic techniques in the analysis of synovial tissue
presents some exciting possibilities for future research.
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recently there has been an upsurge in the use of arthro-
scopic techniques by rheumatologists, particularly those
interested in the pathogenesis of arthritis and the effects
of new therapeutic strategies [10]. Initially, arthroscopy
required hospitalisation and a general anaesthetic. The
production of high-definition, small-bore arthroscopes
(1–2.7mm), and the development of local and regional
anaesthesia protocols [11,12], have permitted day-case
arthroscopy to move from the operating theatre to proce-
dure rooms, and even to the outpatient clinic [13].
Synovial biopsy in routine clinical practice
Synovial biopsy is not normally required for routine diag-
nostic or therapeutic purposes in patients with established
arthritis. However, examination of synovial tissue can
assist in the diagnosis of some joint infections [14]. In
acute bacterial arthritis, the synovial membrane contains
clusters or sheets of polymorphonuclear leukocytes. Bac-
teria can be demonstrated in synovial tissue by Gram’s
stain. Sometimes, cultures of synovial tissue may be posi-
tive even when blood and synovial fluid cultures have been
negative. In chronic infections, such as tuberculosis and
fungal diseases, characteristic synovial lesions may be
focal, and multiple biopsies are advised. Mycobacterial
granulomas in the synovium do not always demonstrate
caseation. With appropriate staining, acid-fast organisms,
fungi and spirochaetes (Lyme disease and secondary
syphilis) can be demonstrated. The presence of bacterial
DNA in synovial biopsy samples can provide important
information in the diagnosis of infectious arthritis [15].
Occasionally, the diagnosis of chronic sarcoidosis is estab-
lished after synovial biopsy [16]. The characteristic histo-
logical feature is a well-defined granuloma. The central area
of the granuloma is occupied by lymphocytes, which are
predominantly CD4+, and by mononuclear phagocytes and
their progeny, including epithelioid cells and multinucleated
giant cells. Caseation is absent, but a small area of fibrinoid
necrosis may be present. The outer zone of the granuloma
is formed by CD4+ and CD8+ lymphocytes, fibroblasts,
mast cells and other immunoregulatory cells.
Both gout and pseudogout can demonstrate tophus-like
deposits in synovial tissue [14]. When handling tissues,
special care is required to preserve the crystalline struc-
tures. Amyloid may be deposited in synovium in patients
with primary amyloidosis, Waldenstrom’s macroglobulin-
emin, multiple myeloma and adult cystic fibrosis [17].
Arthropathy associated with ochronosis and haemachro-
matosis demonstrate characteristic histological features.
Pigmented villonodular synovitis, multicentric reticulohisti-
ocytosis and rare tumours of the synovial membrane
require a biopsy for diagnosis.
Synovial biopsy can have a major role in the diagnosis of
monarticular arthritis. A closed needle biopsy of the knee
joint might provide sufficient tissue for histological,
immunohistological and microbiological analysis. An open
biopsy or needle arthroscopic biopsy is the procedure of
choice when other joints are involved, and should be
undertaken in the knee joint if closed needle biopsy fails to
yield a diagnosis.
Synovial biopsy in rheumatoid arthritis
Established rheumatoid arthritis
General comments
The diagnosis of RA after the chronic polyarticular mani-
festations have become established is usually based on
characteristic clinical, radiological and serological mani-
festations. Histological confirmation is not required. The
gross changes that are characteristic of RA result from
chronic synovial inflammation. Typically, the surface of the
synovium becomes hypertrophic and oedematous, with an
intricate system of prominent villous fronds that extend
into the joint cavity. Microscopic evaluation of synovial
tissue inflammation in RA confirms marked cellular hyper-
plasia in the lining layer. T cells, plasma cells,
macrophages, B cells, neutrophils, mast cells, natural killer
cells and dendritic cells accumulate in the synovial sublin-
ing layer (reviewed in [18]). The appearances are not spe-
cific for RA. The dominant cell populations in the lining
layer are fibroblast-like synoviocytes and macrophages,
which release an array of proinflammatory cytokines and
their inhibitors, promoting further intra-articular perturba-
tions. There is abundant production of matrix metallopro-
teinases (MMPs), cysteine proteases and other
tissue-degrading mediators, which accumulate in the syn-
ovial fluid and augment joint damage by interacting directly
with exposed cartilage matrix. These features are present
very early in the disease course. T cells and plasma cells
are prominent in the synovial sublining layer. Perivascular
T cell aggregates are observed in 50–60% of patients
with RA. These aggregates can be surrounded by plasma
cells. There are two basic patterns of T cell infiltration.
First, perivascular lymphocyte aggregates can be found,
which consist predominantly of CD4+ cells in association
with B cells, few CD8+ cells, and dendritic cells. The
second pattern of T cell infiltration is the diffuse infiltrate of
T cells scattered throughout the synovium. A subset of the
CD4+ T cells in synovial tissue is activated. A possible bio-
logical effect of activated perivascular T cells in the syn-
ovium is the stimulation of migrating macrophage
populations through direct cell contact. This mechanism is
known to stimulate macrophage production of cytokines
and MMPs in vitro. Many of the synovial tissue T cells are,
however, in a state of hyporesponsiveness. Interdigitating
dendritic cells, which are potent antigen-presenting cells,
are located in proximity to CD4+ T cells in the lymphocyte
aggregates and near the intimal lining layer. In addition,
macrophages and lymphocytes infiltrate the areas
between the lymphocyte aggregates. The macrophages
often constitute the majority of inflammatory cells in the273
synovial sublining layer. B cells constitute a small propor-
tion of the total number of lymphocytes in the synovial sub-
lining layer. However, numerous plasma cells may be
present throughout the synovium, sometimes exceeding
the number of infiltrating T cells.
An issue that frequently arises in the context of possible
associations between synovial tissue immunohistology
and progressive structural damage relates to the acquisi-
tion of tissue samples from a knee joint and the evaluation
of radiographic images, usually of the hands and feet.
Such studies make the assumption that the immunohisto-
logical appearances in a knee joint are representative of
pathophysiological events occurring at other sites. Evi-
dence to support this hypothesis comes from a study of
patients with RA who underwent biopsy of a knee joint
and a small upper-limb joint on the same day [19]. Another
important issue that requires consideration is the question
of selection bias. This issue has been evaluated exten-
sively, confirming that despite the degree of histological
variation within a joint, representative measures of inflam-
mation can be obtained by examining a limited area of
tissue [20–23].
The intensity of the cellular infiltrate, the levels of activation
and the amount of secreted products vary greatly between
individual patients with RA and other arthropathies
[20,24,25]. Many studies of synovial tissue have been
reported that indicate associations between immunohisto-
logical features of inflammation and clinical measures of
disease activity [20,26,27], as well as with local measures
of synovitis [28]. The immunohistological measures of syn-
ovitis observed in the knee joint are reflected in other
joints from the same patient biopsied at the same time
[19]. Clinically uninvolved joints in patients with RA
demonstrate similar immunohistological changes, although
less intensely than in the affected joints [29,30]. Serial
synovial biopsies in open therapeutic studies and in ran-
domised clinical trials showed that the immunohistological
features of RA and other arthropathies change after treat-
ment with disease-modifying anti-rheumatic drugs
(DMARDs) [26,31–37], oral corticosteroids [38] and tar-
geted biological agents [39–42]. The mediators of inflam-
mation that have been shown to change in therapeutic
studies include mononuclear cell populations
[26,31,32,35,36,39,40,42], adhesion molecule expres-
sion [35,36,38–40,42], levels of cytokine production
[31,33,35,36,41] and MMPs [34,36,37]. Thus, synovial
tissue analysis in patients with RA has revealed several
surrogate markers of disease activity and response to
treatment.
The value of synovial biopsy
In contrast to the studies of disease status and response
to treatment in patients with established arthritis, limited
attention has been given to the study of the immunohisto-
logical appearances and associations with disease
outcome. One cross-sectional analysis demonstrated sig-
nificant correlations between the number of lining layer
and sublining layer macrophages, but not other mononu-
clear cell populations, and joint damage scores in RA [27].
A longitudinal study highlighted the association between
the number of synovial tissue macrophages at baseline
and increases in the joint damage scores over 1 year [43].
Other investigators showed that the predominant change
in the synovial tissue of patients in remission after treat-
ment with DMARDs was a striking decrease in the number
of macrophages [44]. These observations are consistent
with the hypothesis that chronic RA is a macrophage-
mediated disorder and that a decrease in synovial
macrophage content should be a primary aim of success-
ful treatment.
Preliminary studies have evaluated possible associations
between the known mediators of inflammation in synovial
tissue, including cytokines, and outcome in established
RA (Table 1). The effect of blockade of tumour necrosis
factor-α (TNF-α) on TNF-α production in synovial tissue
was evaluated in patients treated with infliximab [41]. All
patients in the study met the American College of
Rheumatology 20% improvement response criteria
(ACR20), and half of the patients met the ACR50.
Patients meeting the ACR50 criteria were those with the
highest baseline levels of TNF-α synthesis. There was a
significant correlation between baseline levels of TNF-α
expression and change in tissue TNF-α levels in response
to therapy. The authors concluded that high levels of syn-
ovial tissue TNF-α production before treatment might
predict responsiveness to anti-TNF-α therapy.
Interleukin-10 (IL-10) is a chondroprotective cytokine and
functions in part by inhibiting the production of TNF-α, IL-1
and MMPs (reviewed in [45]). Treatment of experimental
models of arthritis with recombinant IL-10 inhibited both
the incidence and the severity of disease. In a cross-sec-
tional biopsy study, IL-10mRNA levels were measured in
synovial tissue from patients with erosive RA and com-
pared with those in patients with chronic non-erosive
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Table 1
Synovial biopsy and the determination of diagnosis or
outcome in established rheumatoid arthritis
Synovial tissue Clinical association References
Number of macrophages Radiographic outcome [27,43]
TNF-α Response to TNF-α blockade [41]
IL-10 Radiographic outcome [46]
VEGF Radiographic outcome [48]
IL, interleukin; TNF, tumour necrosis factor; VEGF, vascular endothelial
growth factor.274
arthritis [46]. The patients with erosive RA were positive
for IgM-rheumatoid factor (IgM-RF+) and had a mean
disease duration of 16.8 years. The patients with non-
erosive arthritis had a mean disease duration of 7 years,
and most were seronegative. Synovial tissue IL-10mRNA
levels were significantly lower in the patients with erosive
RA (P<0.03). This observation from a cross-sectional
analysis of patients with established RA was extended in a
longitudinal study of IL-10 polymorphisms in 291 consec-
utive patients with early RA. During the first 6 years of
follow-up, the increase in radiographic damage scores in
the patients who were homozygous for the genotype
–1082AA was significantly less than the increase in
patients with the genotype –1082GG. The smaller
number of erosions in patients with RA who had the
–1082AA genotype could not be explained by other deter-
minants of progressive joint damage, such as an increased
concentration of IgM-RF, the presence of the shared
epitope, or the baseline radiographic damage score.
Taken together, these observations suggested that
increased expression of IL-10mRNA in synovial tissue
might be required for protection against progressive
erosive disease, and that patients with RA who have differ-
ent IL-10 genotypes have a different disease course.
Future research is necessary to confirm whether or not
there is a baseline threshold of tissue IL-10mRNA expres-
sion that will identify individual patients with early RA who
are more likely to demonstrate an aggressive disease
course.
Synovial angiogenesis, a mechanism that is central to syn-
ovial proliferation and pannus formation, is largely depen-
dent on vascular endothelial growth factor (VEGF) [47]. In
a small study of patients with RA, synovial tissue samples
were evaluated for the presence of VEGF at the time of
joint replacement surgery and, on average, 10 years later
[48]. An association between the amount of VEGF pro-
duction in endothelial cells and the rate of progressive
joint damage was suggested. Further studies of proinflam-
matory cytokines, tissue-degrading enzymes, angiogenic
factors and other mediators of inflammation and damage
in the synovium, at the level of either gene expression or
protein production, might reveal characteristics associated
with a favourable or unfavourable outcome.
Early rheumatoid arthritis
General comments
The approach to treating patients with early RA has
changed substantially in recent years. In most centres,
early arthritis refers to patients who present within 1 year
of the onset of symptoms. This change has occurred for
several reasons. First, there has been a growing recogni-
tion that irreversible structural damage can occur very
early in the course of inflammatory arthritis [49]. Second,
the establishment of dedicated early arthritis clinics facili-
tates the early referral of patients with inflammatory arthri-
tis [50]. Third, there is a wider recognition of reliable diag-
nostic factors [51]. Fourth, rheumatologists have access
to effective therapeutic modalities that greatly reduce the
rate of progressive joint damage [52–54]. Last, it has
been established that DMARD therapy reduces the rate of
progressive joint damage more effectively when intro-
duced within 6 months of the onset of symptoms [55]. It is
therefore now standard practice to introduce conventional
DMARDs, such as methotrexate, and even targeted bio-
logical therapies, as first-line treatments in patients with
RA [56].
The presence of some autoantibodies, including IgM-RF
and anti-citrulline-containing peptide (anti-CCP) antibody,
facilitates an early diagnosis of RA [57]. In addition,
several clinical and laboratory factors at baseline reliably
predict outcome. These include higher baseline joint
counts, a high titre of IgM-RF, an elevated acute-phase
response, the number of baseline erosions and the shared
epitope [58]. However, these factors were identified in
large cohorts and do not always apply to individual
patients. Some clinical investigators have developed algo-
rithms that incorporate selected prognostic factors to
predict outcome [59,60].
The value of synovial biopsy
Studies of synovial tissue to identify indicators of outcome
in RA, and changes after treatment, have been necessarily
limited in size in comparison with similar studies that evalu-
ated clinical and serum factors. Synovial biopsy is an inva-
sive procedure and, when performed at arthroscopy, is
technically complicated and expensive. Quantification of
changes with digital image analysis is also costly and
requires considerable expertise. However, the pathophysi-
ological events occurring in tissue are more likely than dis-
persed serum factors to reflect the clinical status and
outcome in individual patients.
Although there is no diagnostic role in early RA, synovial
biopsy and tissue analysis may provide important prognos-
tic information. A few biopsy studies have been reported
that examined mediators of synovial tissue inflammation
and joint damage that were found to be associated with
unfavourable clinical and radiological outcomes (Table 2).
In a limited longitudinal study of patients with early inflam-
matory arthritis, and a mean disease duration of
9.6 months (range 2 weeks to 18 months), the number of
synovial lining layer macrophages at baseline was corre-
lated with the number of new erosions on radiographs of
the hands and feet 1 year later (P=0.002) [25]. Most
patients had RA. In all patients who developed new joint
erosions it was observed that more than 60% of the infil-
trating lining layer cells were macrophages, suggesting
that an immunohistological analysis of synovial tissue at
baseline might identify individual patients who were at
increased risk of developing a more aggressive disease
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course. This observation is similar to the findings in
patients with established RA [27,43]. Macrophages are
the primary source of the proinflammatory cytokines IL-1
and TNF-α, which induce the production of MMPs by
fibroblast-like synoviocytes. Employing in situ hybridisation
techniques, it was observed that the number of MMP-1-
producing cells in the synovial lining layer, in contrast to
cells producing cathepsin B and cathepsin L, seemed to
be strongly correlated with the number of new erosions
that developed during the first year of follow-up
(P=0.0007) [25].
In a similar early synovitis cohort, the expression of
MMP-2, MMP-9, MMP-14 and TIMP-2 (tissue inhibitor of
metalloproteinases-2) was quantified in synovial tissue
biopsies obtained at baseline [61]. Radiographs of the
hands and feet were repeated after 1 year. The synovial
tissue samples from patients who developed joint erosions
had significantly higher levels of MMP-2 than those from
the patients who did not develop erosions (P=0.04).
There seemed to be considerable overlap between the
groups, and the authors did not distinguish between
MMP-2 expression in the lining and sublining layers. Nev-
ertheless, the observation suggested that baseline tissue
MMP-2 levels might be a marker for more aggressive syn-
ovial inflammation.
Early undifferentiated arthritis
General comments
With the emergence of convincing scientific evidence that
very early introduction of disease-modifying therapies
inhibits progressive structural damage more effectively
[55], it is inevitable that some patients who receive treat-
ment will not meet the ACR criteria for RA and will have a
self-limiting, non-progressive arthritis. Thus, clinicians will
seek a balance between exploiting the early ‘window of
opportunity’ in some patients, and delaying effective treat-
ment until the appearance of sufficient diagnostic criteria
in others. About 30% of patients have an undifferentiated
inflammatory arthritis at the time of their first presentation
to an early arthritis clinic [50]. Similarly, a diagnosis of RA
can be established in about 30% of patients. During the
period of follow-up, many of the patients with undifferenti-
ated arthritis will develop features that enable a diagnosis
of RA, or other categories of arthritis. Several factors have
been identified that distinguish groups of patients with
undifferentiated arthritis who acquire a diagnosis of RA.
Thus, the presence in the serum of anti-perinuclear factor
[62], anti-RA33 [63], anti-Sa [64], anti-keratin [65], anti-
filaggrin [66] and anti-CCP antibodies [51] has been
associated with the diagnosis or outcome of RA. In addi-
tion, high-titre antibody against serum amyloid A in
patients attending an early arthritis clinic with undifferenti-
ated arthritis was associated with a subsequent diagnosis
of RA [67].
The value of synovial biopsy
Some studies employing synovial tissue analysis to identify
early diagnostic markers in patients with undifferentiated
arthritis have been reported (Table 3). In one study, a syn-
ovial biopsy was obtained from 95 patients who presented
with unclassified arthritis for less than 12 months [68]. The
objective was to determine which immunohistological
markers could best distinguish RA from other categories
of arthritis. Using regression analytic approaches, it was
observed that high scores for CD38+ plasma cells and
CD22+ B cells were the best discriminating markers when
comparing RA with non-RA categories. The authors con-
cluded that immunohistochemical analysis of synovial
tissue samples could be used to distinguish patients with
RA from other diagnostic categories.
In another study, immunohistological differences between
RA and other categories of arthritis were also observed in
71 patients, including 16 who had had RA for less than
12 months [69]. The intensity of infiltration by both T and
B cells, and differential expression of αV integrin, seemed
to distinguish patients with RA from those with spondy-
larthritis and those with osteoarthritis. The disease dura-
tion of RA did not influence the findings. However, the
immunohistological features highlighted in both of these
studies seem insufficiently disease-specific for routine use
as diagnostic markers.
The demonstration of intracellular citrullinated proteins in
synovial tissue samples from 18 of 36 patients with RA,
and in none of 52 patients with spondylarthritis,
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Table 2
Synovial biopsy and the determination of diagnosis or
outcome in early rheumatoid arthritis
Synovial tissue Clinical association Reference
Number of macrophages Radiographic outcome [25]
MMP-1 Radiographic outcome [25]
MMP-2 Radiographic outcome [61]
MMP, matrix metalloproteinase.
Table 3
Synovial biopsy and the determination of diagnosis or
outcome in undifferentiated arthritis
Synovial tissue Clinical association References
B cells Diagnosis RA [68,69]
Plasma cells Diagnosis RA [68,69]
Integrin expression Diagnosis RA [69]
Citrullinated protein Diagnosis RA [70]
RA, rheumatoid arthritis.276
osteoarthritis and other categories of arthritis, suggested a
useful method of discriminating RA from other inflamma-
tory joint diseases [70]. This observation was the first
description of a specific histological marker for RA in syn-
ovial tissue. The specificity of intracellular citrullinated pro-
teins to RA is the subject of continuing investigation, and it
is clear that further biochemical characterisation of the cit-
rullinated proteins present in the synovium of patients with
RA, and other inflammatory joint diseases, is required
[71,72]. Nevertheless, the possibility that demonstrating
intracellular citrullinated protein in synovial tissue might be
a new tool for the early diagnosis of undifferentiated arthri-
tis is an important prospect.
Future challenges
There is increasing emphasis on the need to recognise
potentially erosive disease in patients presenting with early
undifferentiated arthritis, before sufficient criteria for RA
have evolved. It is likely that pathophysiological pathways
that directly or indirectly result in bone and cartilage
degradation are preferentially activated in articular tissues
from the earliest phases of the disease. The recognition of
enhanced proinflammatory or degradative pathways, or
the downregulation of inhibitory factors, that participate in
the progression or prevention of arthritis, is most likely to
emerge from studies of articular tissues. The preliminary
studies of synovial tissues reported here support this
hypothesis. The inclusion of pharmacogenomic and pro-
teomic techniques in the analysis of synovial tissue from
patients with different categories and stages of arthritis
presents some exciting possibilities for future research.
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